Compound 5-O-Sulfamoyl Adenosine Enhances Cancer Drug Sensitivity by Targeting NSD1 Protein
Researchers report that 5-O-sulfamoyl adenosine (5-SA) inhibits the NSD1 histone methyltransferase enzyme, suppressing cancer cell growth and enhancing the effectiveness of the chemotherapy drug 5-Fluorouracil (5-FU). NSD1 is an epigenetic regulator whose overexpression is associated with poor cancer prognosis and tumor development. The findings suggest a potential new strategy for sensitizing tumors to existing chemotherapy, though the work remains at the preclinical stage.
A study posted to bioRxiv describes the identification and testing of 5-O-sulfamoyl adenosine (5-SA) as an inhibitor of NSD1, a histone methyltransferase enzyme implicated in cancer progression. In biochemical assays, 5-SA demonstrated an IC50 of approximately 54 µM against NSD1, outperforming the structural analog S-Adenosyl-l-Cysteine (SAC), which showed an IC50 of 115 µM. In prostate cancer (DU145) and liver cancer (HepG2) cell lines, 5-SA reduced cell viability, impeded proliferation and migration, altered cell cycle progression, and induced apoptosis, while also lowering NSD1 RNA and protein expression and reducing H3K36me2 histone methylation. Notably, 5-SA enhanced the anticancer activity of 5-FU in cell-based assays, and in a mouse xenograft model of prostate cancer, the combination of 5-SA and 5-FU synergistically reduced tumor growth and improved animal survival compared to either agent alone. The authors claim this is the first report demonstrating that NSD1 inhibition via 5-SA can sensitize tumors to 5-FU. The study was conducted entirely in preclinical models, and the work has not yet undergone peer review.
What's missing
As a preprint, this study has not been peer-reviewed. Key limitations include the use of only two cancer cell lines and a single xenograft model, with no pharmacokinetic, toxicity, or off-target profiling data reported. The mechanism by which 5-SA reduces NSD1 RNA and protein expression — beyond direct enzymatic inhibition — is not fully explained. The generalizability of the 5-FU sensitization effect to other cancer types or chemotherapy agents remains untested.
What different sources said
- bioRxivCenter
Inhibition of NSD1 by 5-O-Sulfamoyl Adenosine improved 5-FU sensitivity by suppressing cancer cell proliferation and xenograft tumor growth
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.